Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD

Blood (2018) 132 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2018-99-116915

Published: 2018

Journal Articles

Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2183.

https://doi.org/10.1182/blood.V130.Suppl_1.2183.2183

Published: 2017

Journal Articles

Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2184.

https://doi.org/10.1182/blood.V130.Suppl_1.2184.2184

Published: 2017

Journal Articles

Economic Impact and Healthcare Utilization in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Routine Clinical Care in the United States (US) - a Claims Database Study

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2185.

https://doi.org/10.1182/blood.V130.Suppl_1.2185.2185

Published: 2017

Journal Articles

Treatment Patterns in Newly Treated and Relapse/Refractory Patients with Follicular Lymphoma in Routine Clinical Care — a United States Electronic Medical Record Database Study

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 4059.

https://doi.org/10.1182/blood.V130.Suppl_1.4059.4059

Published: 2017

Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD

Blood (2017) 130 (Supplement 1): 2622.

https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622

Published: 2017

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

Journal Articles

Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Aaron Galaznik, MD, Jill A Bell, PhD, Meredith M Hoog, MPH, Michael E Stokes, MPH, Anna W Steenrod, MPH, Kevin B Knopf, MD, Brian Seal, RPh, MBA, PhD, Yaping Shou, MD PhD

Blood (2016) 128 (22): 3562.

https://doi.org/10.1182/blood.V128.22.3562.3562

Published: 2016

Journal Articles

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood (2016) 128 (22): 624.

https://doi.org/10.1182/blood.V128.22.624.624

Published: 2016

Journal Articles

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Adam M. Petrich, MD, Leo I. Gordon, MD, Jeffrey R. Infante, MD, Sumit Madan, MD, Francis J. Giles, MD, Halla S. Nimeiri, MBBS, Jason B. Kaplan, MD, Kate Stumpo, Bin Zhang, ScD, Stephanie Faucette, PharmD, PhD, Yaping Shou, MD PhD, Kent C. Shih, MD

Blood (2015) 126 (23): 2693.

https://doi.org/10.1182/blood.V126.23.2693.2693

Published: 2015

Journal Articles

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Gabriel Etienne, MD, PhD, Carmino De Souza, MD, PhD, Mineo Kurokawa, MD, Matt Kalaycio, MD, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, Albert Hoenekopp, MD, Yaping Shou, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Gianantonio Rosti, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2755.

https://doi.org/10.1182/blood.V118.21.2755.2755

Published: 2011

Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Blood (2011) 118 (21): 3770.

https://doi.org/10.1182/blood.V118.21.3770.3770

Published: 2011

Journal Articles

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ian W. Flinn, MD, PhD, Yeow-Tee Goh, MBBS, MD, Pedro Enrique Dorlhiac-Llacer, MD, Kimmo Porkka, MD, PhD, Mineo Kurokawa, MD, PhD, Carmino DeSouza, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Ariful Haque, Hagop Kantarjian, MD, Timothy P. Hughes, MD, MBBS

Blood (2010) 116 (21): 3431.

https://doi.org/10.1182/blood.V116.21.3431.3431

Published: 2010

Journal Articles

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Hagop M. Kantarjian, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Jim Wang, PhD, Jorge Cortes-Franco, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 1129.

https://doi.org/10.1182/blood.V114.22.1129.1129

Published: 2009

Journal Articles

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Jerald P. Radich, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Enrico Gottardi, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Lan Beppu, Yaping Shou, MD, PhD, Ariful Haque, MS, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 1130.

https://doi.org/10.1182/blood.V114.22.1130.1130

Published: 2009

Journal Articles

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Simona Soverini, PhD, Enrico Gottardi, Lan Beppu, Martin C Müller, MD, Ariful Haque, MS, Yaping Shou, MD, PhD, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Giovanni Martinelli, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD

Blood (2009) 114 (22): 3292.

https://doi.org/10.1182/blood.V114.22.3292.3292

Published: 2009

Journal Articles

Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Andreas Hochhaus, MD, Dong-Wook Kim, MD, PhD, Giovanni Martinelli, MD, Timothy P. Hughes, MD, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Philipp Erben, MD, Ariful Haque, Yaping Shou, MD, PhD, Giuseppe Saglio, MD, Jerald P. Radich, MD

Blood (2008) 112 (11): 3216.

https://doi.org/10.1182/blood.V112.11.3216.3216

Published: 2008

Journal Articles

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Andreas Hochhaus, MD, Philipp Erben, MD, Susan Branford, PhD, Jerald Radich, MD, D.W. Kim, MD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Martin C. Mueller, MD, Jana Hoffmann, Francesca Palandri, Simona Soverini, MD, Timothy Hughes, MD, Yaping Shou, MD PhD, Aaron Weitzman, MD, Michele Baccarani, MD

Blood (2006) 108 (11): 749.

https://doi.org/10.1182/blood.V108.11.749.749

Published: 2006

NARROW

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States

Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States

Economic Impact and Healthcare Utilization in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Routine Clinical Care in the United States (US) - a Claims Database Study

Treatment Patterns in Newly Treated and Relapse/Refractory Patients with Follicular Lymphoma in Routine Clinical Care — a United States Electronic Medical Record Database Study

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only